vs
Protalix BioTherapeutics, Inc.（PLX）与美国合众银行（SFBC）财务数据对比。点击上方公司名可切换其他公司
美国合众银行的季度营收约是Protalix BioTherapeutics, Inc.的1.0倍（$9.5M vs $9.1M），美国合众银行同比增速更快（1.5% vs -49.9%），美国合众银行自由现金流更多（$7.0M vs $1.6M），过去两年美国合众银行的营收复合增速更高（5.5% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
美国合众银行是一家美国跨国银行机构，总部位于明尼苏达州明尼阿波利斯，在特拉华州注册成立。截至2025年，它是美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构，主营银行、投资、抵押贷款等相关金融服务。
PLX vs SFBC — 直观对比
营收规模更大
SFBC
是对方的1.0倍
$9.1M
营收增速更快
SFBC
高出51.5%
-49.9%
自由现金流更多
SFBC
多$5.4M
$1.6M
两年增速更快
SFBC
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $9.5M |
| 净利润 | $-5.5M | — |
| 毛利率 | 49.4% | — |
| 营业利润率 | -51.1% | 27.1% |
| 净利率 | -60.3% | — |
| 营收同比 | -49.9% | 1.5% |
| 净利润同比 | -184.8% | — |
| 每股收益（稀释后） | $-0.06 | $0.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXSFBC
| Q4 25 | $9.1M | $9.5M | ||
| Q3 25 | $17.9M | $9.8M | ||
| Q2 25 | $15.7M | $10.4M | ||
| Q1 25 | $10.1M | $9.2M | ||
| Q4 24 | $18.2M | $9.4M | ||
| Q3 24 | $18.0M | $9.1M | ||
| Q2 24 | $13.5M | $8.6M | ||
| Q1 24 | — | $8.6M |
净利润PLXSFBC
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $2.4M | $1.7M | ||
| Q2 25 | $164.0K | $2.1M | ||
| Q1 25 | $-3.6M | $1.2M | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $3.2M | $1.2M | ||
| Q2 24 | $-2.2M | $795.0K | ||
| Q1 24 | — | $770.0K |
毛利率PLXSFBC
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
营业利润率PLXSFBC
| Q4 25 | -51.1% | 27.1% | ||
| Q3 25 | 11.9% | 21.3% | ||
| Q2 25 | 7.5% | 24.5% | ||
| Q1 25 | -41.0% | 15.9% | ||
| Q4 24 | 39.6% | 24.6% | ||
| Q3 24 | 22.2% | 15.6% | ||
| Q2 24 | -18.0% | 11.4% | ||
| Q1 24 | — | 10.9% |
净利率PLXSFBC
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | 17.3% | ||
| Q2 25 | 1.0% | 19.8% | ||
| Q1 25 | -35.8% | 12.7% | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | 12.7% | ||
| Q2 24 | -16.4% | 9.2% | ||
| Q1 24 | — | 9.0% |
每股收益（稀释后）PLXSFBC
| Q4 25 | $-0.06 | $0.87 | ||
| Q3 25 | $0.03 | $0.66 | ||
| Q2 25 | $0.00 | $0.79 | ||
| Q1 25 | $-0.05 | $0.45 | ||
| Q4 24 | $0.10 | $0.74 | ||
| Q3 24 | $0.03 | $0.45 | ||
| Q2 24 | $-0.03 | $0.31 | ||
| Q1 24 | — | $0.30 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $138.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $109.4M |
| 总资产 | $82.3M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXSFBC
| Q4 25 | $14.7M | $138.5M | ||
| Q3 25 | $13.6M | $101.2M | ||
| Q2 25 | $17.9M | $102.5M | ||
| Q1 25 | $19.5M | $131.5M | ||
| Q4 24 | $19.8M | $43.6M | ||
| Q3 24 | $27.4M | $148.9M | ||
| Q2 24 | $23.4M | $135.1M | ||
| Q1 24 | — | $138.0M |
股东权益PLXSFBC
| Q4 25 | $48.2M | $109.4M | ||
| Q3 25 | $52.9M | $107.5M | ||
| Q2 25 | $49.9M | $106.0M | ||
| Q1 25 | $45.2M | $104.4M | ||
| Q4 24 | $43.2M | $103.7M | ||
| Q3 24 | $32.4M | $102.2M | ||
| Q2 24 | $28.6M | $101.3M | ||
| Q1 24 | — | $101.0M |
总资产PLXSFBC
| Q4 25 | $82.3M | $1.1B | ||
| Q3 25 | $82.3M | $1.1B | ||
| Q2 25 | $78.5M | $1.1B | ||
| Q1 25 | $73.9M | $1.1B | ||
| Q4 24 | $73.4M | $993.6M | ||
| Q3 24 | $61.6M | $1.1B | ||
| Q2 24 | $91.5M | $1.1B | ||
| Q1 24 | — | $1.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $7.2M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $7.0M |
| 自由现金流率自由现金流/营收 | 17.8% | 73.4% |
| 资本支出强度资本支出/营收 | 4.4% | 1.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $12.0M |
8季度趋势，按日历期对齐
经营现金流PLXSFBC
| Q4 25 | $2.0M | $7.2M | ||
| Q3 25 | $-3.7M | $3.8M | ||
| Q2 25 | $-5.2M | $-494.0K | ||
| Q1 25 | $-5.1M | $1.9M | ||
| Q4 24 | $4.0M | $2.9M | ||
| Q3 24 | $4.1M | $3.3M | ||
| Q2 24 | $-3.6M | $-4.0M | ||
| Q1 24 | — | $3.5M |
自由现金流PLXSFBC
| Q4 25 | $1.6M | $7.0M | ||
| Q3 25 | $-4.2M | $3.8M | ||
| Q2 25 | $-5.7M | $-518.0K | ||
| Q1 25 | $-5.4M | $1.8M | ||
| Q4 24 | $3.6M | $2.9M | ||
| Q3 24 | $4.0M | $3.2M | ||
| Q2 24 | $-3.8M | $-5.6M | ||
| Q1 24 | — | $1.9M |
自由现金流率PLXSFBC
| Q4 25 | 17.8% | 73.4% | ||
| Q3 25 | -23.7% | 38.3% | ||
| Q2 25 | -36.2% | -5.0% | ||
| Q1 25 | -53.0% | 19.8% | ||
| Q4 24 | 19.6% | 30.4% | ||
| Q3 24 | 22.4% | 35.5% | ||
| Q2 24 | -28.1% | -65.4% | ||
| Q1 24 | — | 22.2% |
资本支出强度PLXSFBC
| Q4 25 | 4.4% | 1.8% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 2.8% | 0.2% | ||
| Q1 25 | 3.0% | 0.4% | ||
| Q4 24 | 2.3% | 0.8% | ||
| Q3 24 | 0.5% | 0.5% | ||
| Q2 24 | 1.3% | 18.7% | ||
| Q1 24 | — | 19.0% |
现金转化率PLXSFBC
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | 2.24× | ||
| Q2 25 | -31.91× | -0.24× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | 2.84× | ||
| Q2 24 | — | -5.05× | ||
| Q1 24 | — | 4.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SFBC
暂无分部数据
